You are here

  • Home
  • Archive
  • Volume 1, Issue Suppl 1
  • Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study

Article info

Article menu

Download PDFPDF

Poster Presentation
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
Free

Authors

Citation

de Gruijl T, Santegoeds S, van Wetering S, et al
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
Journal for ImmunoTherapy of Cancer 2013;1:P205. doi: 10.1186/2051-1426-1-S1-P205

Publication history

  • First published November 7, 2013.
Online issue publication 
November 07, 2013

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2013